RecruitingNot Applicable

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Thailand40 participantsStarted 2018-08-01

Plain-language summary

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Diagnosis of neovascular glaucoma
✓. The patients having IOP \> 21 mmHg, having the indication for trabeculectomy
✓. The patients' age of at least 18-year-old
✓. The patients having visual potential at least hand motion.
✓. Present of NVI or NVA.
✓. Willing and able to provide informed consent to participate in the study
✓. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

✕. One eye patient
✕. Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
✕. Cannot obtain endothelial cell count.
✕. History of bevacizumab or fluorescence dye allergy.
✕. Active infectious ocular disease including endophthalmitis and corneal ulcer
✕. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
✕. Has or planning to be pregnant or breastfeeding

regression of nevolascularization

Timeframe: 2 months

NCT IDNCT03648814

SponsorPrince of Songkla University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-01

Assoc.Prof.Weerawat Kiddee, MD